Download PDF
Diabetologie und Stoffwechsel 2024; 19(01): 58-63
DOI: 10.1055/a-2035-9351
Originalarbeit

100 Jahre Insulin: Wie hat sich die Insulintherapie bei Erwachsenen zwischen 2000 und 2021 verändert?

100 years of insulin: how insulin therapy changed between 2000 and 2021
Sigrun R. Merger 
1   Klinik für Endokrinologie und Diabetologie, Klinikum Coburg GmbH, Coburg, Germany (Ringgold ID: RIN15020)
,
Alexander Eckert
2   Institut für Epidemiology und medizinische Biometrie, Universität Ulm, Ulm, Germany (Ringgold ID: RIN9189)
,
Peter Bramlage
3   Institut für Pharmakologie und Präventive Medizin, IPPMed, Cloppenburg, Germany (Ringgold ID: RIN566322)
,
Gregor M. Hess
4   Internistische Gemeinschaftspraxis Dres. Hess und Diabetologische Schwerpunktpraxis, Internistische Gemeinschaftspraxis Dres. Hess und Diabetologische Schwerpunktpraxis, Worms, Germany
,
Thomas Haak
5   Innere Medizin, Diabetes Zentrum Mergentheim, Bad Mergentheim, Germany
,
Reinhard Welp
6   Hygiene, Knappschaftskrankenhaus Bottrop GmbH, Bottrop, Germany (Ringgold ID: RIN39545)
,
Christian Wagner
7   Diabetes Schwerpunktpraxis, Praxis, Surheim, Germany
,
Markus Laimer
8   Diabetologie, Endokrinologie, Ernährungsmedizin, Inselspital Universitatsspital Bern, Bern, Switzerland (Ringgold ID: RIN27252)
,
Peter Jehle
9   Innere Medizin, Evangelisches Krankenhaus Paul Gerhardt Stift, Lutherstadt Wittenberg, Germany (Ringgold ID: RIN39663)
,
Reinhard Walter Holl
10   ZIBMT, Institute of Epidemiology and Medical Biometry, Ulm, Germany
› Author AffiliationsSupported by: Robert-Koch-Institut
Supported by: Bundesministerium für Bildung und Forschung Ministerium DZD, grant number: 82DZD14E03
Supported by: Deutsche Diabetes Gesellschaft
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Erratum: 100 Jahre Insulin: Wie hat sich die Insulintherapie bei Erwachsenen zwischen 2000 und 2021 verändert?Diabetologie und Stoffwechsel 2024; 19(01): e1-e1
DOI: 10.1055/a-2088-4440

Zusammenfassung

100 Jahre nach Einführung der Insulintherapie haben sich durch pharmakologische Weiterentwicklung der Insuline mit vielfältigen Wirkdauern, aber auch Veränderungen der Applikations- und Messmöglichkeiten, die angewendeten Insulintherapien insbesondere in den letzten 20 Jahren stark verändert, hin zu einer häufigeren Anwendung von Insulinanaloga, insbesondere bei Patienten mit T1DM [1]. Bei Typ-2-DM ergibt sich mit unterschiedlichen Strategien der Insulintherapie auch in Kombination mit oralen Antidiabetika für die Patienten ein breites Spektrum an Formen der Insulintherapie. Durch die verschiedenen Applikationsformen und Insuline zeigt sich eine kleine, aber signifikante Verbesserung der Blutzuckereinstellung, aber vor allem eine Individualisierung der Diabetestherapie.

Abstract

100 years after using insulin therapy for the very first time, pharmacological advances in medicine – especially in terms of insulin preparations with different kinetics, but also different methods of application and glucose self measurement – have brought about quite drastic changes, particularly within the last 20 years. Today, the use of insulin analogues has become far more common, in particular for patients with T1DM. For patients with T2DM there now is a broad spectrum of different forms of insulin therapy: BOT, BOTplus, SIT, various pre-mixtures of insulin, conventional or intensive conventional insulin therapy, or even the use of insulin pumps for few patients. The numerous different insulins and methods of application have led to a small but quite significant improvement in the blood-sugar levels of patients and have further advanced the individuality in patient care.

Schlüsselwörter

Insulin - Diabetes - Typ 1 Diabetes - Typ 2 Diabetes - insulin therapy - T1DM - T2DM


Publication History

Received: 15 December 2022

Accepted after revision: 14 February 2023

Article published online:
21 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Dittrich HM, Hahn von Dorsche H. The anatomical and histological investigation of the pancreas in the 19th century and till the discovery of insulin (1921). 1. The anatomical pancreas research from the beginning till the discovery of islets of pancreas (1869) (author’s transl). Anat Anz 1978; 143: 221-230 (PMID: 356672)
    PubMedGoogle Scholar
  • 2 Weinstock RS, Schutz-Fuhrmann I, Connor CG. et al. Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. Diabetes Res Clin Pract 2016; 122: 28-37 DOI: 10.1016/j.diabres.2016.09.024. (PMID: 27764721)
    CrossrefPubMedGoogle Scholar
  • 3 Bramlage P, Tittel SR, Müther S. et al. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type-1 diabetes. Acta Diabetologica 2022; 59: 1453-1460
    CrossrefPubMedGoogle Scholar
  • 4 Schöttler H, Auzanneau M, Best F. et al. Insulinpumpe, kontinuierliche und kapilläre Glukosemessung bei Kindern, Jugendlichen und Erwachsenen mit Diabetes mellitus: Daten des DPV-Registers zwischen 1995 -2019. Diabetologie und Stoffwechsel 2020; 15: 477-486
    Article in Thieme ConnectGoogle Scholar
  • 5 Grammes J, Kustner E, Dapp A. et al. Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy: data from the German/Austrian DPV registry. Diabet Med 2020; 37: 856-862 DOI: 10.1111/dme.14218. (PMID: 31853984)
    CrossrefPubMedGoogle Scholar
  • 6 Vliebergh J, Lefever E, Mathieu C. Advances in newer basal and bolus insulins: impact on type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2021; 28: 1-7 DOI: 10.1097/MED.0000000000000599. (PMID: 33315628)
    CrossrefPubMedGoogle Scholar
  • 7 Xu J, Yao D, Xia J. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis. J Clin Pharm Ther 2021; 46: 1245-1253 DOI: 10.1111/jcpt.13398.
    CrossrefPubMedGoogle Scholar
  • 8 Mark Gv, Lanzinger S, Sziegoleit S. et al. Characteristics of patients with type 1 or type 2 diabetes receiving insulin glargine U300 – an analysis of 7,268 patients based on the DPV and DIVE registries. Advances in Therapy 2019; 36: 1628-1641
    CrossrefPubMedGoogle Scholar
  • 9 Melmer A, Zurrer I, Kopp F. et al. Differences in insulin dosing in women with type 1 diabetes before and after the menopause. Swiss Med Wkly 2021; 151: w30025 DOI: 10.4414/smw.2021.w30025.
    CrossrefPubMedGoogle Scholar
  • 10 Benioudakis E, Karlafti E, Kalaitzaki A. et al. Technological Developments and Quality of Life in Type 1 Diabetes Mellitus Patients: A Review of the Modern Insulin Analogues, Continuous Glucose Monitoring and Insulin Pump Therapy. Curr Diabetes Rev 2022; 18: e031121197657 DOI: 10.2174/1573399818666211103163208. (PMID: 34732118)
    CrossrefPubMedGoogle Scholar
  • 11 Bain S, Feher M, Fisher M. et al. A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. Diabet Med 2020; 37: 219-228 DOI: 10.1111/dme.14180. (PMID: 31729775)
    CrossrefPubMedGoogle Scholar
  • 12 Mannucci E, Caiulo C, Naletto L. et al. Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine 2021; 74: 508-517 DOI: 10.1007/s12020-021-02889-6. (PMID: 34599695)
    CrossrefPubMedGoogle Scholar
  • 13 Prinz N, Schwandt A, Borgert B. et al. Not All Type-2-Diabetes Patients Increase Body Mass Index After Initiating Insulin: Results of Latent Class Analysis from the DPV Registry. Diabetes Technol Ther 2021; 23: 799-806 DOI: 10.1089/dia.2021.0144.
    CrossrefPubMedGoogle Scholar
  • 14 van Mark G, Tittel SR, Welp R. et al. DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus. BMJ Open Diabetes Res Care 2021; 9 DOI: 10.1136/bmjdrc-2021-002215.
    CrossrefPubMedGoogle Scholar
  • 15 Bohn B, Bramlage P, Wagner C. et al. Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-Analogon Glargin U300 im Vergleich zu Patienten mit Glargin U100? Eine multizentrische Analyse von 14.123 Patienten mit Insulin Glargin aus den Diabetesregistern DPV und DIVE. Wiener Medizinische Wochenschrift 2018; 168: 415-422
    CrossrefPubMedGoogle Scholar
  • 16 Farmer AJ, Oke J, Stevens R. et al. Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. Diabetes Obes Metab 2011; 13: 1136-1141 DOI: 10.1111/j.1463-1326.2011.01475.x. (PMID: 21767341)
    CrossrefPubMedGoogle Scholar
  • 17 Persano M, Nollino L, Sambataro M. et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci 2021; 25: 923-931 DOI: 10.26355/eurrev_202101_24661.
    CrossrefPubMedGoogle Scholar
  • 18 Pfohl M, Siegmund T, Pscherer S. et al. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Vasc Health Risk Manag 2015; 11: 569-578 DOI: 10.2147/VHRM.S82720. (PMID: 26604774)
    CrossrefPubMedGoogle Scholar